Pharmadrug Inc.
PHRX
CNSX
09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 23.20K | 15.30K | 271.50K | 463.90K | 75.50K |
Depreciation & Amortization | 9.20K | 9.20K | 9.30K | 19.30K | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 37.10K | 1.70K | 329.00K | 524.80K | 133.30K |
Operating Income | -37.10K | -1.70K | -329.00K | -524.80K | -133.30K |
Income Before Tax | -132.70K | -105.20K | -401.40K | -9.83M | -223.70K |
Income Tax Expenses | -- | -- | -- | -742.60K | -- |
Earnings from Continuing Operations | -132.70K | -105.20K | -401.40K | -9.09M | -223.70K |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | 44.90K | -- |
Net Income | -132.70K | -105.20K | -401.40K | -9.04M | -223.70K |
EBIT | -37.10K | -1.70K | -329.00K | -524.80K | -133.30K |
EBITDA | -27.90K | 7.50K | -319.70K | -519.90K | -131.10K |
EPS Basic | 0.00 | 0.00 | 0.00 | -0.12 | 0.00 |
Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
EPS Diluted | 0.00 | 0.00 | 0.00 | -0.12 | 0.00 |
Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
Average Basic Shares Outstanding | 104.14M | 100.39M | 94.91M | 73.54M | 50.80M |
Average Diluted Shares Outstanding | 104.14M | 100.39M | 94.91M | 73.54M | 50.80M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |